Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

10.44 +0.15 (+1.41%)
Delayed Quote Updated: 12:12 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 Next >
News headline image
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript ↗
NERLYNX demand surged 12% year over year as Puma raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Puma Biotechnology Q2 Earnings Call Highlights ↗
Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The... 
Via MarketBeat
Topics Earnings
Puma Biotechnology (NASDAQ:PBYI) Beats Q2 Estimates, but Soft Q3 Guidance Tempers Reaction ↗
Via Chartmill
News headline image
Puma (PBYI) Q1 2026 Earnings Call Transcript ↗
Puma (PBYI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) Beats Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Puma Biotechnology (NASDAQ:PBYI) Beats Q4 Estimates, Guides for Profitable 2026 ↗
Via Chartmill
News headline image
Puma Biotechnology Q1 Earnings Call Highlights ↗
Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million,... 
Via MarketBeat
Topics Earnings
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool
News headline image
Puma Biotech (PBYI) Earnings Call Transcript ↗
Puma Biotech (PBYI) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Where Puma Biotechnology Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Puma Biotechnology (NASDAQ:PBYI) Tops Q3 2025 Estimates and Raises Full-Year Outlook ↗
Puma Biotech's Q3 2025 earnings beat expectations, driven by strong NERLYNX sales. The company raised its full-year revenue guidance and advances its clinical pipeline. 
Via Chartmill
Topics Earnings
News headline image
Puma (PBYI) Q2 Revenue Rises 11% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment. 
Via Benzinga
Topics Intellectual Property
News headline image
PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 ↗
PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
3 Strong Buy Stocks Under $5: January 2024 ↗
A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Nanobiotix Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares surged 39.3% to $0.6621 in pre-market trading after gaining around 14% on Wednesday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning! 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.